
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory… NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIR...
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory… NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIR...